CO6640262A2 - Composiciones farmacéuticas y métodos para su elaboración - Google Patents

Composiciones farmacéuticas y métodos para su elaboración

Info

Publication number
CO6640262A2
CO6640262A2 CO12221016A CO12221016A CO6640262A2 CO 6640262 A2 CO6640262 A2 CO 6640262A2 CO 12221016 A CO12221016 A CO 12221016A CO 12221016 A CO12221016 A CO 12221016A CO 6640262 A2 CO6640262 A2 CO 6640262A2
Authority
CO
Colombia
Prior art keywords
methods
pharmaceutical compositions
preparation
pazopanib
weight
Prior art date
Application number
CO12221016A
Other languages
English (en)
Inventor
Manish Gupta
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of CO6640262A2 publication Critical patent/CO6640262A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas que incluyen una cantidad de una sal de adición de ácido de pazopanib equivalente a 10 miligramos/mililitro de pazopanib, y del 2 al 13 por ciento en peso/peso de una ciclodextrina modificada adecuada para utilizarse en una formulación oftálmica, así como métodos para la elaboración de las mismas.
CO12221016A 2010-05-05 2012-12-05 Composiciones farmacéuticas y métodos para su elaboración CO6640262A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05

Publications (1)

Publication Number Publication Date
CO6640262A2 true CO6640262A2 (es) 2013-03-22

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12221016A CO6640262A2 (es) 2010-05-05 2012-12-05 Composiciones farmacéuticas y métodos para su elaboración

Country Status (26)

Country Link
US (3) US20120028918A1 (es)
EP (1) EP2566331B1 (es)
JP (1) JP5835717B2 (es)
KR (1) KR20130071434A (es)
CN (1) CN102970871A (es)
AR (1) AR081364A1 (es)
AU (1) AU2011247995B2 (es)
BR (1) BR112012028291A2 (es)
CA (1) CA2798386A1 (es)
CL (1) CL2012003075A1 (es)
CO (1) CO6640262A2 (es)
CR (1) CR20120556A (es)
DO (1) DOP2012000281A (es)
EA (1) EA201291168A1 (es)
ES (1) ES2519615T3 (es)
HK (1) HK1175947A1 (es)
IL (1) IL222751A0 (es)
MA (1) MA34286B1 (es)
MX (1) MX2012012837A (es)
NZ (1) NZ603411A (es)
PE (1) PE20130217A1 (es)
SG (1) SG185087A1 (es)
TW (1) TW201206908A (es)
UY (1) UY33367A (es)
WO (1) WO2011140343A1 (es)
ZA (1) ZA201208265B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
RS61758B1 (sr) 2011-09-16 2021-05-31 Forsight Vision4 Inc Aparati za razmenu tečnosti
WO2013123413A2 (en) * 2012-02-17 2013-08-22 Pharmacyclics, Inc. Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CN104160762B (zh) * 2012-03-08 2019-03-15 三星电子株式会社 用于控制无线通信系统中的服务的方法
CA2905496A1 (en) * 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
PT3039424T (pt) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
CN107106551A (zh) * 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法
RU2708958C2 (ru) 2014-11-10 2019-12-12 Форсайт Вижн4, Инк. Расширяемые устройства доставки лекарственных средств и способы использования
JP6818264B2 (ja) 2014-12-25 2021-01-20 国立大学法人京都大学 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー
MX2018012021A (es) 2016-04-05 2019-01-24 Forsight Vision4 Inc Dispositivos de administracion de farmacos oculares implantables.
EP3612223B1 (en) * 2017-04-17 2024-07-31 National Institute Of Biological Sciences, Beijing Treating male senescence
US11174253B2 (en) 2017-08-02 2021-11-16 Alphala Co., Ltd. Compound and pharmaceutical composition containing the same
WO2019234632A1 (en) * 2018-06-07 2019-12-12 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
PT1968594E (pt) * 2005-11-29 2010-11-18 Glaxosmithkline Llc Tratamento de distúrbios neovasculares oculares tais como degeneração macular, estrias angióides, uveite e edema macular
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007121483A2 (en) * 2006-04-18 2007-10-25 Ekr Therapeutics, Inc. Pre-mixed, ready-to-use iv bolus compositions and methods of use
US20090155176A1 (en) * 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック, インコーポレイテッド ピラゾロピリミジンpi3k阻害剤化合物および使用方法
WO2011009016A1 (en) * 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
US20120232102A1 (en) * 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
TW201201808A (en) * 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion

Also Published As

Publication number Publication date
IL222751A0 (en) 2012-12-31
US20150231265A1 (en) 2015-08-20
EP2566331B1 (en) 2014-09-03
CR20120556A (es) 2013-02-20
JP5835717B2 (ja) 2015-12-24
BR112012028291A2 (pt) 2015-09-15
ES2519615T3 (es) 2014-11-07
UY33367A (es) 2011-10-31
ZA201208265B (en) 2013-07-31
KR20130071434A (ko) 2013-06-28
SG185087A1 (en) 2012-12-28
NZ603411A (en) 2014-10-31
EA201291168A1 (ru) 2013-06-28
CN102970871A (zh) 2013-03-13
MX2012012837A (es) 2013-01-24
AR081364A1 (es) 2012-08-29
TW201206908A (en) 2012-02-16
CA2798386A1 (en) 2011-11-10
EP2566331A1 (en) 2013-03-13
MA34286B1 (fr) 2013-06-01
HK1175947A1 (en) 2013-07-19
JP2013525501A (ja) 2013-06-20
DOP2012000281A (es) 2013-05-31
PE20130217A1 (es) 2013-03-21
US20120028918A1 (en) 2012-02-02
EP2566331A4 (en) 2013-09-18
US20110281901A1 (en) 2011-11-17
CL2012003075A1 (es) 2013-03-08
AU2011247995A1 (en) 2012-12-13
WO2011140343A1 (en) 2011-11-10
AU2011247995B2 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
CO6640262A2 (es) Composiciones farmacéuticas y métodos para su elaboración
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
TR201905586T4 (tr) Amorf dapagli̇flozi̇n i̇çeren formülasyonlar
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
GT201200307A (es) NUEVOS DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
CY1123456T1 (el) Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων
CR20120542A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112012033755A2 (pt) composições e métodos antissépticos estáveis
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
UY33634A (es) ?combinaciones sinérgicas de triazoles, estrobirulinas y benzimidazoles, usos, formulaciones, procedimientos de producción y aplicaciones utilizando las mismas?.
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112014027582A8 (pt) composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
FR2980709B1 (fr) Compositions contenant de la spermine et compositions pharmaceutiques les contenant
CL2013003588A1 (es) Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa.
BR112013012719A2 (pt) "compostos como moduladores de receptor com utilidade terapêutica".

Legal Events

Date Code Title Description
FC Application refused